# Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

> **NCT04583592** · PHASE2 · COMPLETED · sponsor: **Sagent Pharmaceuticals Inc.** · enrollment: 295 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Camostat Mesilate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04583592
- **Lead sponsor:** Sagent Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2022-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04583592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04583592, "Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04583592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*